Talquetamab China cohort safety report details mostly mild GPRC5D-related adverse events

원문 링크: WordPress 원문

Researchers reporting the MonumenTAL-1 China cohort reported through PubMed on September 1, 2026 that 41 adults in China with heavily pretreated relapsed/refractory multiple myeloma received talquetamab, and the reported GPRC5D-associated adverse events were mainly grade 1-2, with 50%-100% resolving by the data cutoffs . The abstract does not report a randomized comparator , so the findings describe monitoring and management needs rather than comparative efficacy .

The new event was the online publication of the MonumenTAL-1 China safety report on September 1, 2026 , making this cohort-specific evidence available for public review.

n = 41 included Chinese adults

50%-100% resolved by data cutoff

1 case dose modification reported

ENG KOROpen ENG

AI-generated conceptual illustration; not study data.

The China cohort centered on treatment-related daily symptoms

The denominator is the 41 adults included in this descriptive China cohort, not every person who receives talquetamab. Participants had heavily pretreated relapsed/refractory multiple myeloma and measurable disease. The report therefore speaks most directly to people with a similar treatment history and disease setting.

Design: Phase I/II cohort safety report. Enrolled: 41 adult Chinese patients. Analysed: QW n = 29 and Q2W n = 12. Focus: incidence, onset, duration, and recovery of GPRC5D-associated adverse events.

The two dosing groups answer a descriptive safety question: what symptoms appeared, how long they lasted, and whether they had recovered by the data cutoffs. They do not create a clean head-to-head test. The QW group received 0.4 mg/kg once weekly, while the Q2W group received 0.8 mg/kg every two weeks.

On-target/off-tumor means an effect in normal tissues that carry the treatment target, not only in a tumor. In this report, the named sites were the mouth, skin, and nails. Median treatment duration was 7.7 months in the QW cohort and 7.1 months in the Q2W cohort, with median follow-up of 16.3 and 13.9 months.

The reported symptoms are part of the treatment conversation

The safety pattern is easy to flatten into the phrase “mostly mild,” but the useful detail is where symptoms occurred and what happened next. The abstract lists oral effects such as dysgeusia and dry mouth, skin effects including rash and non-rash skin toxicity, and nail disorders. These are practical changes a care team can ask about rather than distant laboratory abstractions.

The report says that 50%-100% of the described adverse events had resolved by the relevant data cutoff. That range is not a single overall response rate. The abstract-level record does not give an event-by-event denominator here, so it cannot tell a reader that every symptom had the same frequency or recovery pattern.

Supportive therapies were used, and one case needed a dose modification for grade 2 weight decrease. The authors describe management without routine dose modification as a way to maintain exposure, but that observation is not proof that symptoms are harmless or that every patient can continue treatment unchanged. A treatment duration measure also should not be mistaken for an antimyeloma response measure.

AI-generated conceptual illustration; not study data.

The abstract sets a narrow boundary around safety interpretation

The most important limit is the evidence type. This is a China cohort report within MonumenTAL-1, not a randomized comparison. The abstract describes the two dosing schedules, but it does not establish which schedule is safer, more effective, or better tolerated. It also does not provide patient-level denominators for each individual symptom.

The safety summary is not uniformly negative or uniformly reassuring. Events were predominantly grade 1-2, yet the QW cohort included one grade 3 non-rash skin toxicity. The abstract also records a dose modification in one case for grade 2 weight decrease. Those details matter because a general statement about tolerability can hide the need for active assessment.

The data cutoffs were February 29, 2024 for QW and August 26, 2024 for Q2W. A recovery reported by a cutoff means recovery was recorded within that observation window; it does not predict later symptoms. Because the two cutoffs are different, the groups were not observed for identical lengths of time. Recovery at a cutoff is not the same as permanent absence of a symptom. The population was heavily pretreated, so the same pattern cannot automatically be transferred to people with a different disease history.

AI-generated conceptual illustration; not study data.

Patient education and early symptom management are the practical follow-up

The authors recommend explaining possible GPRC5D-associated effects before treatment and managing them when they appear. That is a clinical communication point, not a promise of maximum benefit. Patients should report changes in taste, dry mouth, rash, other skin changes, nail problems, and weight to the treating team, who can judge severity and the appropriate response.

The next useful layer of evidence would separate each event by cohort and denominator, then show onset, duration, recovery, supportive treatment, dose changes, and longer follow-up together. The current abstract gives the direction of the safety experience, but it does not answer how often each symptom occurs in a comparable population or how these observations relate to tumor response.

What changed on September 1 is that a China-specific safety report became available for readers to inspect. What did not change is the need to interpret this small, non-randomized cohort within its original setting. It is a source for questions about symptom monitoring, not a standalone treatment recommendation.

A reader can hold two ideas together here. The report is specific enough to prepare a conversation about symptoms before and during treatment, while the lack of a comparator means it cannot rank talquetamab against another option. The cohort and its limits are part of the result, not a footnote added afterward.

Evidence boundary This article reports what the PubMed abstract states about a defined China cohort. It does not add an efficacy result, a comparison with another treatment, or a patient-level rate for each adverse event that the abstract does not provide. References PubMed record: Clinical features and management of GPRC5D-associated adverse events PubMed EFetch record Publisher DOI record This article is for public education and is not medical advice. Treatment choices and symptom management belong with the patient’s clinical team.